ISOTRETHINOINE IN ACNE THERAPY
- Authors: Tlish M.M.1, SHavilova M.E.1
-
Affiliations:
- Kuban State Medical University
- Issue: Vol 93, No 4 (2017)
- Pages: 90-96
- Section: DRUG TREATMENT IN DERMATOVENEROLOGY
- URL: https://journals.rcsi.science/0042-4609/article/view/116917
- DOI: https://doi.org/10.25208/0042-4609-2017-93-4-90-96
- ID: 116917
Cite item
Full Text
Abstract
Systemic retinoids are known to be the most effective means of treating severe forms of acne. However, in spite of longstanding and intensive practice of their application in dermatology, some specialists still avoid prescribing this group of drugs. As a rule, this is due to lack of awareness of health professionals about therapy techniques and means of correcting possible adverse events. We discuss the clinical aspects of administration of isotretinoin in treatment of moderate and severe forms of acne. Practical recommendations are given on how to prevent various myths, misconceptions and prejudices in health professionals and patients. We present our own experience of using isotretinoin with increased bioavailability (Acnecutan®*).
Keywords
About the authors
M. M. Tlish
Kuban State Medical University
Author for correspondence.
Email: marina@netzkom.ru
Sedina str., bldg 4, Krasnodar, 350063, Russia Russian Federation
M. E. SHavilova
Kuban State Medical University
Email: fake@neicon.ru
Sedina str., bldg 4, Krasnodar, 350063, Russia Russian Federation
References
- Rocha M. A., Costa C. S., Bagatin E. Acne vulgaris: an inflammatory disease even before the onset of clinical lesions. Inflamm Allergy Drug Targets 2014; 13 (3): 162—7.
- Kubanova A. A., Kubanov A. A., Samcov A. V., Aravijskaya E. R. Akne. Federal'nye klinicheskie rekomendacii. Dermatovenerologiya: Bolezni kozhi. Infekcii, peredavaemye polovym putem. 5-e izd., pererab. i dop. M.: Delovoj ehkspress, 2016: 9—27. [Кубанова А. А., Кубанов А. А., Самцов А. В., Аравийская Е. Р. Акне. Федеральные клинические рекомендации. Дерматовенерология: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд., перераб. и доп. М: Деловой экспресс, 2016: 9—27.] Литература
- Nast A., Dreno B., Bettoli V. et al. European Evidence-based (S3). Guideline for the Treatment of Acne. Update 2016.
- Harms M. Isotretinoin: 10 years on. Dermatology 1993; 186: 81—82.
- Ganceviciene R., Zouboulis C. C. Isotretinoin: state of the art treatment for acne vulgaris. J Dtsch Dermatol Ges 2010; 8 (1): S47—59.
- Rademaker M. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Australas J Dermatol 2013; 54 (3): 157—162.
- Kubanova A. A., Araviyskaya Ye. R., Sokolovsky Ye. V., Dvorova Ye. K., Fadeyeva Ye. I. Systematic treatment of strong forms of acne: the use of isotretinoin in the Russian Federation. Vestn dermatol venerol 2013; (5): 102— 114. [Кубанова А. А., Аравийская Е. Р., Соколовский Е. В., Дворова Е. К., Фадеева Е. И. Системное лечение тяжелых форм акне: опыт и спользования изотретиноина в Российской Федерации. Вестн дерматол и венерол 2013; (5): 102—114.]
- Tlish M. M. Experience of treating acne patients with acnecutan. Vestn dermatol venerol 2011; (3): 142—152. [Тлиш М. М. Опыт лечения больных акне препаратом Акнекутан. Вестн дерматол венерол 2011; (3): 142—152.]
- Tlish M. M., Yelistratova A. S., Gluzmin M. I. Practical aspects of administering Acnecutan for the treatment of acne in teenagers. Vestn dermatol venerol 2013; (4): 85—90. [Тлиш М. М., Елистратова А. С., Глузмин М. И. Практические аспекты применения изотретиноина в лечении акне у подростков. Вестн дерматологи и венерол 2013; (4): 85—90.]
- Strauss J. S., Stranieri A. M. Changes in longterm sebum production from isotretinoin therapy. J Am Acad Dermatol 1982; 6: 751—6.
Supplementary files
